サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1544104

予測検査と予兆検査の世界市場

Predictive and Presymptomatic Testing

出版日
ページ情報
英文 159 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
予測検査と予兆検査の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 159 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

予測検査と予兆検査の世界市場は2030年までに104億米ドルに到達

2023年に55億米ドルと推定される予測検査と予兆検査の世界市場は、2030年には104億米ドルに達し、分析期間2023-2030年のCAGRは9.5%で成長すると予測されます。

米国市場は14億米ドル、中国はCAGR 12.6％で成長予測

米国の予測検査と予兆検査市場は2023年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに24億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは12.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.5％と7.5％と予測されています。欧州では、ドイツがCAGR 7.4%で成長すると予測されています。

世界の予測検査と予兆検査市場- 主要動向と促進要因まとめ

予測検査と予兆検査：健康リスクの予測

予測検査と予兆検査では、症状が現れる前に、遺伝子検査やその他の診断検査を用いて、個人の特定疾患の発症リスクを評価します。これらの検査は、DNA、タンパク質、その他のバイオマーカーを分析し、がん、心臓病、神経変性疾患などの疾患の発症可能性の上昇に関連する変異やその他の指標を特定します。予測検査は通常、特定の疾患の家族歴がある人に使用され、リスクを軽減したり発症を遅らせたりする早期介入や予防措置を可能にします。一方、症候前検査は、無症候性の個人が、家系内に存在することが知られている遺伝性疾患を発症するかどうかを判定するために使用されます。これらの検査の主な目的は、個人とヘルスケア提供者に、医学的決定とライフスタイルの変更の指針となる貴重な情報を提供し、最終的に健康転帰を改善することです。

技術の進歩はどのように予測検査と予兆検査を向上させているか？

技術の進歩は予測検査と予兆検査の精度、アクセシビリティ、範囲を大幅に向上させました。次世代シーケンサー（NGS）の進歩により、ゲノムの大きなセグメントを迅速かつコスト効率よく解析することが可能になり、疾患リスクに関連する遺伝的変異をより広範囲に同定できるようになりました。より高感度で特異的なバイオマーカーの開発により、症状が現れる前であっても疾患の初期徴候を検出する能力が向上しました。さらに、バイオインフォマティクスと機械学習アルゴリズムの統合により、遺伝子データの解釈が強化され、より正確なリスク評価と個別化された知見が提供されるようになった。また、消費者直販の遺伝子検査サービスの台頭により、予測検査へのアクセスが増加し、従来の臨床の場を必要とすることなく、個人が自分の健康リスクについて洞察を得ることができるようになった。このような技術的改善により、予測検査と予兆検査の用途と影響は拡大し、プロアクティブヘルスケアのための貴重なツールとなっています。

予測検査と予兆検査の主な用途と利点は？

予測検査と予兆検査はヘルスケアの様々な分野で応用され、病気の予防と管理を強化する多くのメリットを提供しています。腫瘍学では、乳がんや卵巣がんに関連するBRCA1/2変異のような遺伝性がんのリスクが高い個人を特定するために予測検査が使用され、早期のサーベイランスや予防措置が可能になります。心臓病学では、遺伝子検査によって家族性高コレステロール血症などに関連する変異を同定し、心臓病予防のための介入を導くことができます。神経学では、ハンチントン病のような疾患について、早期診断が家族計画や生活習慣の選択に役立つ無症候性検査が有益です。さらに、予測検査は薬理ゲノミクスにおいて、特定の薬物に対する個人の反応を決定するために使用され、有効性を最適化し、副作用を最小限に抑える個別化された治療計画を可能にします。予測検査と予兆検査の主な利点には、症状が現れる前に疾患リスクを特定する能力があり、早期介入、個別化ヘルスケア、患者の転帰の改善を可能にします。個人の遺伝的素因に関する貴重な洞察を提供することで、これらの検査は積極的な健康管理と情報に基づいた意思決定を後押しします。

予測検査と予兆検査市場の成長を促進する要因は？

予測検査と予兆検査市場の成長は、いくつかの要因によって牽引されています。疾患リスクにおける遺伝の役割に対する認識の高まりと、個別化ヘルスケアに対する需要の高まりは、これらの検査が個別の治療・予防戦略を導く貴重な情報を提供するため、重要な促進要因となっています。遺伝子検査の精度、スピード、手頃な価格を向上させる技術の進歩も、市場の成長を後押ししています。これらの検査を一般の人々にとってより利用しやすくする、消費者直接遺伝子検査サービスの拡大は、需要をさらに押し上げています。さらに、予防ヘルスケアと疾患の早期発見への注目の高まりが、予測検査と予兆検査の採用拡大に寄与しています。AIやバイオインフォマティクスなどの高度なデータ分析ツールの統合は、これらの検査の有用性と精度を高め、継続的な成長を促進しています。これらの要因は、遺伝子検査技術における継続的な技術革新と相まって、予測検査と予兆検査市場の持続的成長を後押ししています。

調査対象企業の例（注目の14社）

  • 23andMe, Inc.
  • Abbott Molecular, Inc.
  • BioAxis DNA Research Centre Private Limited
  • Color Genomics, Inc.
  • Direct Laboratory Services LLC（DirectLabs）
  • Gene by Gene Ltd.
  • Genomic Diagnostics
  • Mapmygenome
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • Positive Bioscience, Inc.
  • Quest Diagnostics, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP14178

Global Predictive and Presymptomatic Testing Market to Reach US$10.4 Billion by 2030

The global market for Predictive and Presymptomatic Testing estimated at US$5.5 Billion in the year 2023, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 12.6% CAGR

The Predictive and Presymptomatic Testing market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global Predictive and Presymptomatic Testing Market - Key Trends and Drivers Summarized

Predictive and Presymptomatic Testing: Anticipating Health Risks

Predictive and presymptomatic testing involves the use of genetic and other diagnostic tests to assess an individual's risk of developing a particular disease before symptoms appear. These tests analyze DNA, proteins, and other biomarkers to identify mutations or other indicators that are associated with an increased likelihood of developing conditions such as cancer, heart disease, or neurodegenerative disorders. Predictive testing is typically used in individuals with a family history of a specific disease, allowing for early intervention and preventive measures that can reduce the risk or delay the onset of the disease. Presymptomatic testing, on the other hand, is used to determine whether an asymptomatic individual will develop a genetic disorder that is known to be present in the family. The primary purpose of these tests is to provide individuals and healthcare providers with valuable information that can guide medical decisions and lifestyle changes, ultimately improving health outcomes.

How Are Technological Advancements Enhancing Predictive and Presymptomatic Testing?

Technological advancements have significantly enhanced the accuracy, accessibility, and scope of predictive and presymptomatic testing. Advances in next-generation sequencing (NGS) have made it possible to analyze large segments of the genome quickly and cost-effectively, allowing for the identification of a broader range of genetic variants associated with disease risk. The development of more sensitive and specific biomarkers has improved the ability to detect early signs of disease, even before symptoms emerge. Additionally, the integration of bioinformatics and machine learning algorithms has enhanced the interpretation of genetic data, providing more accurate risk assessments and personalized insights. The rise of direct-to-consumer genetic testing services has also increased access to predictive testing, enabling individuals to gain insights into their health risks without the need for traditional clinical settings. These technological improvements have expanded the applications and impact of predictive and presymptomatic testing, making it a valuable tool for proactive healthcare.

What Are the Key Applications and Benefits of Predictive and Presymptomatic Testing?

Predictive and presymptomatic testing is applied in various areas of healthcare, offering numerous benefits that enhance disease prevention and management. In oncology, predictive testing is used to identify individuals at high risk of hereditary cancers, such as BRCA1/2 mutations associated with breast and ovarian cancer, enabling early surveillance and preventive measures. In cardiology, genetic testing can identify mutations linked to conditions like familial hypercholesterolemia, guiding interventions to prevent heart disease. Neurology benefits from presymptomatic testing for disorders such as Huntington's disease, where early diagnosis can inform family planning and lifestyle choices. Additionally, predictive testing is used in pharmacogenomics to determine how individuals will respond to specific medications, allowing for personalized treatment plans that optimize efficacy and minimize adverse effects. The primary benefits of predictive and presymptomatic testing include the ability to identify disease risks before symptoms appear, enabling early intervention, personalized healthcare, and improved patient outcomes. By providing valuable insights into an individual's genetic predispositions, these tests empower proactive health management and informed decision-making.

What Factors Are Driving the Growth in the Predictive and Presymptomatic Testing Market?

The growth in the predictive and presymptomatic testing market is driven by several factors. The increasing awareness of the role of genetics in disease risk and the growing demand for personalized healthcare are significant drivers, as these tests provide valuable information that can guide individualized treatment and prevention strategies. Technological advancements that enhance the accuracy, speed, and affordability of genetic testing are also propelling market growth. The expansion of direct-to-consumer genetic testing services, which make these tests more accessible to the general population, is further boosting demand. Additionally, the rising focus on preventive healthcare and the early detection of diseases are contributing to the increased adoption of predictive and presymptomatic testing. The integration of advanced data analysis tools, such as AI and bioinformatics, is enhancing the utility and accuracy of these tests, driving their continued growth. These factors, coupled with the ongoing innovation in genetic testing technologies, are driving the sustained growth of the predictive and presymptomatic testing market.

Select Competitors (Total 14 Featured) -

  • 23andMe, Inc.
  • Abbott Molecular, Inc.
  • BioAxis DNA Research Centre Private Limited
  • Color Genomics, Inc.
  • Direct Laboratory Services LLC (DirectLabs)
  • Gene by Gene Ltd.
  • Genomic Diagnostics
  • Mapmygenome
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • Positive Bioscience, Inc.
  • Quest Diagnostics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Predictive and Presymptomatic Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Genetic Testing Propel Market Dynamics
    • Increasing Awareness of Preventive Healthcare Expands Addressable Market Opportunity
    • Government Initiatives for Genomic Research Strengthens Business Case
    • Growing Adoption of Direct-to-Consumer Genetic Tests Throws the Spotlight on Innovation
    • Focus on Early Disease Detection and Prevention Accelerates Market Demand
    • Expansion of Genetic Counseling Services Boosts Market Prospects
    • Rising Prevalence of Genetic Disorders Enhances Market Growth
    • Integration of AI and Big Data in Genetic Analysis Drives Market Dynamics
    • Increasing Investments in Genomic Research and Development Propels Market Expansion
    • Focus on Reducing Healthcare Costs Sustains Market Growth
    • Growing Use of Predictive Testing in Oncology Expands Market Reach
    • Focus on Regulatory Approvals and Reimbursement Policies Enhances Market Opportunities
    • Rising Consumer Interest in Ancestry and Health Insights Spurs Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Predictive and Presymptomatic Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Predictive and Presymptomatic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Predictive and Presymptomatic Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION